BioPharmaSpec GmbH

BioPharmaSpec was formed in 2014 by Prof Howard Morris (with over 45 years of experience in protein characterization and founder of the M-Scan group of companies) and Dr Andrew Reason (with over 25 years of experience in commercialization of analytical methods for characterizing biopharmaceuticals and previously Group Manager of the European M-Scan laboratories and SGS M-Scan Europe).
Scientists who are now part of the BioPharmaSpec team originally pioneered the now well-accepted strategies of mass spectrometric peptide mapping, the use of mass spectrometry in disulfide bridge assignment and the discovery and characterization of important glycosylation in natural and recombinant proteins. They continue to be involved in cutting edge discovery research and development as illustrated recently in a collaborative publication with US researchers including the FDA, or in our efforts in the fight against the Coronavirus (SARS-CoV-2) COVID-19 pandemic.
We support a broad range of biopharmaceutical characterization studies. Our clients use our analytical data to support many different areas of analytical characterization, such as choosing the best cell clone by assessing critical structural attributes, performing batch-to-batch or innovator to biosimilar comparisons, or adding HCP-MS to their host cell protein detection strategies.